Efficacy of rituximab (RTX), a monoclonal anti-CD20 antibody, has been suggested in a recent controlled trial in polyneuropathies with antibodies against myelin-associated glycoprotein (PN-MAG) [1] . Aims of this study were to evaluate the efficacy and safety of RTX in PN-MAG and to search for predictive factors of response to treatment.
Dear Sirs, Efficacy of rituximab (RTX), a monoclonal anti-CD20 antibody, has been suggested in a recent controlled trial in polyneuropathies with antibodies against myelin-associated glycoprotein (PN-MAG) [1] . Aims of this study were to evaluate the efficacy and safety of RTX in PN-MAG and to search for predictive factors of response to treatment.
Six patients fulfilling diagnosis criteria for PN-MAG [2] received four weekly infusions of RTX (375 mg/m 2 ). Clinical status of each patient was evaluated, before treatment (M0) then every 3 months during 9 months, by assessing Overall Neuropathy Limitation Scale (ONLS) [3] , INCAT Sensory Score (ISS) [4] , and MRC sum score on 28 muscle groups [5] . Anti-MAG titers (Buhlmann ELISA technique) and B cells expressing CD19 blood count were concomitantly quantified. Nerve conduction studies were performed before treatment and 9 months after (M9), on fibular, tibial, median and ulnar nerves [5] . Treatment was considered efficient only when ONLS score decreased by at least 1 point at M9. Demographic, clinical, biological and electrophysiological status before RTX, were statistically compared between patients with efficient and non-efficient response to treatment using the MannWhitney and Fisher's exact tests. The level of statistical significance was set at p = 0.05. Patients were asked to give informed consent for use of data in a journal publication.
Mean age of patients (70 years old, range 57-86 years), duration before treatment from onset of the disease (5 years, range 2-10 years), main clinical manifestations of each patient and previous immunotherapies are detailed in Table 1 . Before RTX treatment, ONLS score ranged from 2 to 6 (mean 3.7) and ISS score from 2 to 12 (mean 6.2). Nine months after the last RTX infusion, ONLS score improved by 1 point in two patients, by 2 points in one, remained stable in the three others. ISS score improved in five patients (mean 3.8 points), MRC score improved in three patients (mean 2.7 points). Decrease of anti-MAG titers was observed in all the six patients at M9 by a mean of 43% (Fig. 1) . By the meantime, IgM monoclonal titers decreased in five patients but did not change in one. As expected, CD19 B-cells blood count dramatically decreased, after treatment and stayed low at M9 (138 9 10 9 /l at M0 vs. 2.5 9 10 9 /l at M3 vs. 40 9 10 9 /l at M9). RTX treatment did not modify the mean CD4 and CD8 lymphocytes blood counts (respectively 674 9 10 9 /l at M0 vs. 789 9 10 9 /l at M9; and 448 9 10 9 /l at M0 vs. 416 9 10 9 /l at M9) as the mean gammaglobulins titers (9.7 g/l at M0 vs. 9 g/l at M9). No change in individual or overall electrophysiological data was evidenced when comparing examination before treatment and 9 months after treatment. No serious adverse event was reported.
Demographic, clinical, biological and electrophysiological data at baseline, including MAG titers and IgM monoclonal titers, were not statistically different in the three patients who improved their ONLS score at M9 compared to the three patients who did not.
Experimental pathogenicity of anti-MAG antibodies has been established in anti-MAG polyneuropathies [6] . RTX is a monoclonal antibody designed to target the B-cells producing anti-MAG antibodies and then expected to reverse the pathogenic process.
In clinical practice, therapeutic benefits of RTX are known to be delayed and are reported to be more evident on sensory deficiency than on functional disability. Our results confirm those of previous studies: improvement of sensory deficiency in half to 2/3 of the treated patients, improvement of the functional disability in less than half of the treated patients, decrease of IgM monoclonal component and of anti-MAG titers respectively by 30-74% and by 44-87%, as assessed 8 or 12 months after the RTX infusions [1, [7] [8] [9] [10] .
In this study, we did not find any predictive factor of response to RTX treatment, including type of the underlying hemopathy and disease duration prior to treatment. Predictive value of anti-MAG antibodies titers is not clear in the literature: RTX is more efficient when anti-MAG antibodies titers are moderately elevated in one study [9] and when titers are high in another [1] . Better improvement was reported in patients with more severe sensory deficit at baseline [1] .
Treatment with RTX improved functional disability in half of our PN-MAG population. Treatment was safe, no serious adverse event occurred during the 9 months of follow up. As no predictive factor of efficacy appears informative, RTX should be reserved for patients impaired in their daily life. Studies in larger cohorts are needed to confirm.
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